Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae:: Contributions of type II topoisomerase mutations and efflux to levels of resistance

被引:108
作者
Bast, DJ
Low, DE
Duncan, CL
Kilburn, L
Mandell, LA
Davidson, RJ
de Azavedo, JCS
机构
[1] Mt Sinai Hosp, Dept Microbiol, Toronto, ON M5G 1X5, Canada
[2] Univ Hlth Network, Toronto, ON, Canada
[3] Toronto Med Labs, Toronto, ON, Canada
[4] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada
[5] McMaster Univ, Div Infect Dis, Hamilton Hlth Sci Corp, Hamilton, ON, Canada
[6] Dalhousie Univ, Dept Microbiol, Queen Elizabeth II Hlth Sci Ctr, Halifax, NS, Canada
关键词
D O I
10.1128/AAC.44.11.3049-3054.2000
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
We report on amino acid substitutions in the quinolone resistance-determining region of type II topisomerases and the prevalence of reserpine-inhibited efflux for 70 clinical isolates of S. pneumoniae for which the ciprofloxacin MIC is greater than or equal to4 mug/ml and 28 isolates for which the ciprofloxacin MIC is less than or equal to2 pg/ml. The amino acid substitutions in ParC conferring low-level resistance (MICs, 4 to 8 mug/ml) included Phe, Tyr, and Ala for Ser-79; Asn, Ala, Gly, Tyr, and Val for Asp-83; Asn for Asp-78; and Pro for Ala-115, Isolates with intermediate-level (MICs, 16 to 32 mug/ml) and high-level (MICs, 64 mug/ml) resistance harbored substitutions of Phe and Tyr for Ser-79 or Asn and Ala for Asp-83 in ParC and an additional substitution in GyrA which included either Glu-85-Lys (Gly) or Ser-ll-Phe (Tyr). Glu-15-Lys was found exclusively in isolates with high-level resistance. Efflux contributed primarily to low-level resistance in isolates with or without an amino acid substitution in ParC. The impact of amino acid substitutions in ParE was minimal, and no substitutions in GyrB were identified.
引用
收藏
页码:3049 / 3054
页数:6
相关论文
共 29 条
  • [1] Fluoroquinolone resistance among recent clinical isolates of Streptococcus pneumoniae
    Barry, AL
    Brown, SD
    Fuchs, PC
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 (03) : 428 - 429
  • [2] COMMUNITY-ACQUIRED PNEUMONIA
    BARTLETT, JG
    MUNDY, LM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (24) : 1618 - 1624
  • [3] Community-acquired pneumonia in adults: Guidelines for management
    Bartlett, JG
    Breiman, RF
    Mandell, LA
    File, TM
    [J]. CLINICAL INFECTIOUS DISEASES, 1998, 26 (04) : 811 - 838
  • [4] Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae
    Brenwald, NP
    Gill, MJ
    Wise, R
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (08) : 2032 - 2035
  • [5] Crystal structure of the breakage-reunion domain of DNA gyrase
    Cabral, JHM
    Jackson, AP
    Smith, CV
    Shikotra, N
    Maxwell, A
    Liddington, RC
    [J]. NATURE, 1997, 388 (6645) : 903 - 906
  • [6] Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada
    Chen, DK
    McGeer, A
    de Azavedo, JC
    Low, DE
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (04) : 233 - 239
  • [7] In vitro development of resistance to five quinolones and amoxicillin-clavulanate in Streptococcus pneumoniae
    Davies, TA
    Pankuch, GA
    Dewasse, BE
    Jacobs, MR
    Appelbaum, PC
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (05) : 1177 - 1182
  • [8] DNA gyrase, topoisomerase IV, and the 4-quinolones
    Drlica, K
    Zhao, XL
    [J]. MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS, 1997, 61 (03) : 377 - +
  • [9] Fass D, 1999, NAT STRUCT BIOL, V6, P322
  • [10] Primary targets of fluoroquinolones in Streptococcus pneumoniae
    Fukuda, H
    Hiramatsu, K
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (02) : 410 - 412